Related Experiment Video
Updated: Aug 7, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
[Gene expression analysis by DNA microarray in papillary thyroid cancer]
Elzbieta Gubała1, Małgorzata Wiench, Małgorzata Oczko-Wojciechowska
1Department of Nuclear Medicine and Endocrine Oncology, Clinic of Oncologic Surgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.
Endokrynologia Polska
|July 4, 2006
Summary
Gene expression profiling in papillary thyroid cancer identified significant changes in 110 genes. Dipeptidylpeptidase 4 (DPP4) showed the most promise as a molecular marker for this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Papillary thyroid cancer (PTC) is the most common endocrine malignancy.
- Understanding gene expression alterations is crucial for identifying diagnostic and therapeutic targets.
Purpose of the Study:
- To analyze the gene expression profile of papillary thyroid cancer using microarray analysis.
- To identify potential molecular markers for PTC diagnosis.
Main Methods:
- High-density oligonucleotide microarrays (GeneChip HG-U133A) were used to analyze 16 PTC tissues and 16 normal thyroid tissues.
- Gene expression data were analyzed using MAS 5.0 software.
- Differential gene expression was assessed, focusing on dipeptidylpeptidase 4 (DPP4), fibronectin 1 (FN1), and tissue inhibitor of metalloproteinase 1 (TIMP1).
Main Results:
- 110 genes exhibited significantly altered expression in PTC compared to normal tissues.
- DPP4-RNA was absent in normal tissue but highly abundant in PTC.
- FN1 and TIMP1 expression, present in normal tissue, were markedly increased in PTC.
- DPP4 demonstrated the most significant differential expression, suggesting it as a potential biomarker.
Conclusions:
- Gene expression profiling reveals distinct molecular signatures in papillary thyroid cancer.
- DPP4 emerges as a highly promising molecular marker for papillary thyroid cancer detection.
- Further validation of DPP4 as a diagnostic biomarker is warranted.
